Laura Brege takes over at Nodality after brief retirement

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

Laura Brege takes over at Nodality after brief retirement

After a 9-month absence from the industry, biotech veteran Laura Brege returned to work, joining San Francisco-based Nodality as its new president and CEO, the company announced this week. Prior to her new appointment, Brege was the chief operating officer and executive vice president at nearby Onyx Pharmaceuticals ($ONXX), until her retirement at the end of last year, according to the San Francisco Business Times. She replaces David Parkinson, who left Nodality earlier this year. Release | Article

 Laura Brege--Nodality
Brege became the company's new president and CEO.


 Frederic Chereau--Shire
Chereau became senior vice president and franchise lead on angioedema.

Biotech

> Frederic Chereau joined Shire ($SHPG) as senior vice president and franchise lead on angioedema for its Human Genetic Therapies business. Release

> MethylGene announced Charles Grubsztajn left the company as president and CEO. Martin Godbout will assume those roles in the interim. Release

> Cardiome Pharma ($CRME) appointed Jennifer Archibald as CFO of the company, after the resignation of Curtis Sikorsky. Release

> Elan ($ELN) appointed Hans Peter Hasler as COO of the company, effective Oct. 1. Release

> Immunovative appointed Bruce Harmon as CFO, effective immediately. Release

> Nephron Pharmaceuticals announced Jerry Webb as chief scientific officer and John Petta as COO. Release

> Eurovaccines appointed Anna-Karin Maltais as chief scientific officer and Emma Berglund as chief business officer. Story

> Enzymatics has hired Jon DiVincenzo as president and CEO. Release

> Forma Therapeutics hired Rob Sarisky as chief business officer. Release

Medical Devices

Israeli devicemaker InspireMD announced that CEO Ofir Paz will step down from his post as part of a planned transition to prepare InspireMD for formal commercialization of its proprietary MGuard embolic protection stent (EPS) platform technology. Release

Pharma

> Savient Pharmaceuticals ($SVNT) appointed John Hamill as senior vice president and CFO. Release

Capsugel made significant changes to its executive leadership team. The company welcomed John Shroyer (senior vice president and CFO), Erasmo Schutzer (senior vice president of marketing and chief marketing officer), Ian Robertson (senior vice president of information technology and chief information officer), Christopher Game (senior vice president of procurement and chief procurement officer), John Cullivan (senior vice president of corporate business development and strategy), Amit Patel (senior vice president and president of dosage form solutions), and Donal Loughrey (senior vice president of operations and supply chain). Release

Drug Delivery

> Emisphere Technologies appointed Alan Rubino as president and CEO. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.